Ergoteles’s Cartesian Therapeutics RNAC Stock Holding History

Ergoteles’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,200	Closed	-$479K	–	1920
2022 Q2	$479K	Buy	+12,200	New	+$362K	0.01%	855

Other funds holding RNAC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Ergoteles's RNAC Position: Q3 2022 in Review

Ergoteles sold out of Cartesian Therapeutics (RNAC) in Q3 2022, closing a stake of 12,200 shares — an estimated $479K sold.

Ergoteles first reported a position in RNAC in Q2 2022 and held it in 1 quarter. The position peaked at $479K in Q2 2022. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

Ergoteles reported no remaining Cartesian Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 12,200 Cartesian Therapeutics shares in Q3 2022, an estimated $479K.
Ergoteles first reported a position in Cartesian Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Cartesian Therapeutics position peaked at $479K in Q2 2022.
96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.